Skip to main content

CCTG Connection



Published:
Category: Group updates
Patient Representative Richard Wassersug
The Canadian Cancer Trials Group would like to acknowledge and send a warm thank you to Richard Wassersug for his commitment and dedication as a CCTG Patient Representative, he will be leaving the committee at the end of 2023. Richard has been a  CCTG patient representative since April 2015 and has been a member of the Genitourinary Disease Site Committee since that time.
 
Richard was diagnosed with prostate cancer over 20 years ago and has had surgery, radiation, and hormone therapy to control his disease.
Read More

Published:
Category: Group updates
2023 CCTG, TTDR and BARL holiday hours
From all of us at CCTG we wish you and your loved ones Happy Holidays, season’s greetings and best wishes for a happy, healthy, and joyous holiday season! We have updated the CCTG central office holiday season hours of operation, TTDR instructions for shipments and BARL holiday closures. Read More

Published:
Category: News
CommNETs workshop

The Commonwealth Neuroendocrine Tumour (CommNETs) Research Collaborative held their annual research workshop on November 12th and 13th in Christchurch New Zealand. With close to 60 people in attendance and at least 20 research projects to complete and develop, the 2023 CommNETs Annual Research Workshop was certainly productive and successful.

Read More

Published:
Category: Publications
CO26 secondary publication
 
Chen EX, Loree JM, Titmuss E, Jonker DJ, Kennecke HF, Berry S, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, Aubin F, Koski S, Wei AC, Tu D, O’Callaghan CJ. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open 6: e2346094-e2346094.
Read More

Published:
Category: Trials
Permanent Trial Closure: CE8
The CE8 trial: A Phase III Trial of Marizomib in Combination with Standard Temozolomide-Based Radiochemotherapy versus Standard Temozolomide-Based Radiochemotherapy Alone in Patients with Newly-Diagnosed Glioblastoma has been permanently closed.
The objective of the study was to compare the overall survival of glioblastoma patients treated with standard TMZ-based radiochemotherapy alone or TMZ-based radiochemotherapy in combination with marizomib.
For more information please visit the CE8 members trial page.
Read More



Published:
Category: Group updates
Welcoming new Patient Representative Haydn Bechthold

CCTG would like to welcome our new Patient Representative Haydn Bechthold who will be supporting the Gastrointestinal Disease Site Committee.

In 2021, at the age of 22, Haydn Bechthold received a stage 3C rectal cancer diagnosis, followed by the identification of Lynch syndrome. Having endured symptoms for over four years before his diagnosis, Haydn recognized the evident gaps in care for young adult cancer patients. This diagnosis abruptly halted his soccer career in Europe, yet it sparked a new passion for patient advocacy.

Read More

Published:
Category: Group updates
CCTG Recruiting for a Patient Representative Volunteer Role
CCTG is currently seeking applications for a Patient Representative for the Hematology Disease Site Committee Read More

Published:
Category: Publications

CCTG will be presenting the following at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California. ASH is the world's largest professional gathering of both clinicians and scientists around the world who are working to conquer blood diseases.


CCTG SC.26: Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Read More